Emerging therapeutic areas in lipid management and CV disease - PACE-CME

Emerging therapeutic areas in lipid management and CV disease

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Icosapent ethyl in post-CABG patients with diabetes
Icosapent ethyl in post-CABG patients with diabetes
Hyperlipidemia
Icosapent ethyl in post-CABG patients with diabetes
- Subodh Verma, MD, PhD
Phase 3 study results of plozasiran in patients with FCS
Phase 3 study results of plozasiran in patients with FCS
Hyperlipidemia
Phase 3 study results of plozasiran in patients with FCS
- Gerald F. Watts, DSc, DM, PhD
Predicting 30-year CV outcomes in women
Predicting 30-year CV outcomes in women
ESC Congress 2024
Predicting 30-year CV outcomes in women
- Paul Ridker, MD
Intensive and early lowering of atherogenic lipids after MI
Intensive and early lowering of atherogenic lipids after MI
ESC Congress 2024
Intensive and early lowering of atherogenic lipids after MI
- Jessica Schubert, MD